CLK2 and breast carcinoma: The targeting of CLK2 with the inhibitor T-025 in an allograft model of MYC-driven spontaneous breast cancer resulted in significant anti-tumour effects, including the induction of skipped exons, of apoptosis, and growth suppression28.